Shawn Leland - 14 Feb 2022 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
President, CEO, Director
Signature
/s/ Tammy Furlong, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
14 Feb 2022
Net transactions value
$0
Form type
4
Filing time
16 Feb 2022, 19:08:39 UTC
Previous filing
24 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Employee Stock Option (Right to Buy) Award $0 +186,500 $0.000000 186,500 14 Feb 2022 Common Stock 186,500 $3.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 10, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date and is subject to acceleration in the event of a change in control of the Issuer.